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Abstract: Neoplastic transformation of germinal center B (GCB) cells may give rise to a variety of different B cell lymphoma subtypes,
most of which show substantial heterogeneity in terms of genetic alterations and clinical features. The mutations observed in cancerrelated genes in GCB cells are related to abnormalities in the immunogenetic mechanisms associated with germinal center reaction.
Recent studies have rapidly identified genomic alterations in B cell lymphomas that may be useful for better subclassification, noninvasive
diagnosis, and prediction of response to therapy. The WHO recognizes different lymphoma subsets classified within 2 major categories
of B cell lymphoma: Hodgkin’s lymphoma (HL) and B cell non-Hodgkin’s lymphoma (NHL), each with distinct genetic aberrations,
including chromosomal translocations, copy number abnormalities, or point mutations. Next-generation sequencing-based technologies
have allowed cancer researchers to identify somatic mutations and gene expression signatures at a rapid pace so that novel diagnostic or
prognostic biomarkers, as well as therapeutic targets, can be discovered much faster than before. Indeed, deep sequencing studies have
recently revealed that lymphoma-specific somatic mutations may be detected in cell-free circulating DNA obtained from the peripheral
blood of B cell lymphoma patients, suggesting the possibility of minimally invasive diagnosis, monitoring, and predicting response to
therapy of B cell lymphoma patients. In this study, the current status of the recurrent genetic aberrations observed during diagnosis and/
or relapse in HL and the major subtypes of B cell NHL (i.e. diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma,
and Burkitt lymphoma) are discussed to shed light on their potential use as noninvasive diagnostic or prognostic biomarkers and to
reveal their role in lymphomagenesis as a target in therapy for newly diagnosed and chemotherapy-resistant cases.
Key words: Hodgkin’s lymphoma, B cell non-Hodgkin’s lymphoma, genetic alterations

1. Introduction
The human immune system uses complex defense
mechanisms made up of cellular and humoral components
that defend our body against a variety of pathogens. Our
body is constantly protected against various microbial
organisms with the help of a functional immune system.
Lymphocytes are a group of white blood cells and critical
cellular components of the immune system which protect
us from pathogenic microorganisms and tumor formation.
Lymphocytes fall into three main categories: B, T, and NK
cells. B lymphocytes differentiate into plasma cells which
secrete antibodies against specific antigens displayed
on pathogens (Slifka et al., 1998). On the other hand, in
addition to their immunoregulatory roles, T and NK cells
are cytotoxic cells with the capacity to kill virus-infected
or neoplastic cells by stimulating apoptosis (Bevan, 2004;
Vivier et al., 2008). Proper functioning of the immune
system depends on a fine balance between activation

and termination of their activation in a timely manner;
otherwise, dysregulated immune cell homeostasis may lead
to uncontrolled growth of immunocytes. Somatic mutations
of genes regulating cancer-associated biological processes
including, but not limited to, cell cycle or apoptosis in
lymphocytes may lead to uncontrolled cell growth, thereby
resulting in the development of various types of lymphoma.
The majority of lymphomas (90%–95%) originate
from B cells undergoing neoplastic transformation
(Küppers, 2005); on the other hand, the cells of origin
of the remaining lymphomas are either T or NK cells. B
cell lymphomas are usually associated with defects in
immunogenetic mechanisms operating as a part of the
germinal center reaction, which plays a role in T cell
dependent B cell activation and immunity (Küppers,
2005). Lymphoma is classified into two main groups:
Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma
(NHL). The first type of lymphoma described in history
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was HL, which was discovered by Thomas Hodgkin (van
Gijn and Gijselhart, 2012). HL constitutes approximately
10% of all lymphomas (Küppers, 2005). The different
types of lymphoma that were discovered after HL include
other B cell lymphoma subtypes (e.g., diffuse large B
cell lymphoma and follicular lymphoma), all of which
are collectively much more frequent than subtypes of
T or NK cell lymphomas. Subtypes of B cell lymphoma
show substantial heterogeneity with respect to genetic
and clinical characteristics. In the following sections, we
discuss the somatic mutations involved in the formation
of various subtypes of B cell lymphoma.
2. Genetic alterations identified in Hodgkin’s lymphoma
HL, first described by Thomas Hodgkin in 1832, is also
known as Hodgkin’s disease (van Gijn and Gijselhart,
2012). The World Health Organization classifies HLs into
two main categories: nodular lymphocyte predominant
HL and classical Hodgkin’s lymphoma (cHL) (Swerdlow et
al., 2016). cHL represents 90%–95% of HLs and has poorer
prognosis compared to the other category (Shanbhag
and Ambinder, 2018). It has four subtypes: 1) nodular
sclerosis (NSCHL); 2) lymphocyte-rich (LRCHL); 3)
mixed-cellularity (MCCHL), and 4) lymphocyte-depleted
(LDCHL). HL develops with clonal proliferation of
multinucleated, special type germinal center B cells called
Reed–Sternberg cells (Kanzler et al., 1996). Hodgkin
Reed–Sternberg (HRS) cells are tumor cells with no B cell
characteristics and do not express the B cell receptor (BCR)
on their surface (Farrell and Jarrett, 2011). Under normal
conditions, these GCB cells are expected to undergo
apoptosis in the absence of BCR signaling. This suggests
that survival signals normally originating from active
BCR signaling need to be sustained through alternative
pathway(s) in HRS cells to compensate for the lack of BCR
expression. In this context, HRS cells keep surviving due
to deregulation of various signal transduction pathways
and transcription factors, especially nuclear factor NF-κB
(Figure 1A). REL locus amplifications are responsible for
activation in roughly 50% of HL cases with constitutively
active NF-κB signaling (Barth et al., 2003). In a significant
proportion of cases, irregular activation of the NF-κB
signaling pathway is believed to be related to loss-offunction mutations in tumor suppressor genes (e.g.,
NFKBIA, TNFAIP3) that inhibit the NF-κB signaling
pathway (Weniger and Küppers, 2016).
Genetic analysis of cHL tumors is often difficult as
tumor cellularity is less than 5% in biopsies. A recent study
involving the microdissection method revealed mutated
genes in the JAK-STAT signaling pathway (i.e. STAT3,
STAT5B, JAK1, JAK2, and PTPN1) in 87% of cHL cases
(Tiacci et al., 2018) (Figure 1B). Moreover, in a significant
fraction of cHL cases, it has been reported that the JAK-
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STAT5 signaling pathway is activated due to mutations in
SOCS1, an inhibitor of this pathway (Weniger et al., 2006).
The LMP2A gene encoded by the Epstein-Barr virus (EBV)
was shown to contribute to the development of EBV+
HLs through inducing transcriptional changes similar
to those in HRS cells (Portis et al., 2003). Chromosomal
translocations involving the BCL6 oncogene were reported
in approximately half of nodular lymphocyte predominant
HL cases (Wlodarska et al., 2003). In the majority of
HLs, gains of MDM2 or loss-of-function mutations of
TP53 have been reported, which suggests that the P53
signaling pathway is probably not functional in cases with
these genetic aberrations (Küppers, 2009) (Figure 1C).
Table 1 shows the recurrent genetic alterations and the
dysregulated biological pathways in HL.
It has been known for a long time that HL cases
respond to anti-CD30 antibody-drug conjugates, even in
the presence of relapse (Falini et al., 1992; Schnell et al.,
2002). However, until recently, the cell of origin of HRS
cells in HL was not clear. A recent study by Weniger et
al. showed that the transcriptomic profile of HRS cells is
highly similar to that of CD30+ B cells, a rare B cell subset
inside germinal centers (Weniger et al., 2018). In the same
study, the transcriptional differences between the CD30+ B
cell subset and HRS cells of HL were compared, and this
showed significant downregulation of genomic stability
regulators and cytokinesis.
3. Genetic alterations in B cell non-Hodgkin’s lymphoma
A great majority of NHL subtypes are B cell NHLs associated
with abnormalities in immunogenetic mechanisms which
operate in germinal center B cell reaction (Küppers, 2005).
In this section, we address recurrent genetic alterations
observed to date in different B cell NHL subtypes and
oncogenic signaling pathway dysregulations associated
with these alterations.
3.1. Diffuse large B cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most
common type of NHL, accounting for 30%–40% of all
cases (Dubois and Jardin, 2018). Based on gene expression
profiling, DLBCL consists of two distinct subtypes, namely
germinal center B cell (GCB) type and activated B cell
(ABC) type (Alizadeh et al., 2000). This study is very
critical in terms of the value of DNA microarray-based
gene expression profiling for identification of new disease
subtypes with prognostic differences, which cannot be
identified with routine histological evaluations. Another
study confirmed that DLBCL cases can be subclassified
into two different molecular groups as GCB and nonGCB type with the tissue microarray (TMA) method
and immunohistochemical analysis of CD10, BCL6, and
MUM1 protein expression (Hans et al., 2004). Subsequent
studies showed that these two DLBCL subtypes are

ESMERAY and KÜÇÜK / Turk J Biol

A)

B)

HL and ABC DLBCL

CARD11

*

TNFAIP3

#

Cytokine

NEMO
IKKα

IKKβ

NFKBIA

p50

REL

STAT3*

P

*

Upregulation of proto -oncogenes

ABC DLBCL

E)

GCB DLBCL, FL

CD79A
CD79B

*

Aberrant histone
methylation

*

Chronic BCR signaling

STAT5B*
STAT5B

TP53

#

P
P

STAT6*
STAT6

G2

Cell cycle

P

BCL2

#

CCND1*

M
G1
R

*

BIRC3

Apoptosis

*

CCND3
MYC

S

*

Inhibition of
apoptosis

*

Aberrant cell cycle activation

Aberrant activation of
the JAK-STAT pathway

EZH2

*

P

MDM2

#

Upregulation of proto-oncogenes

Aberrant activation of
the NFKB pathway

D)

P

STAT3

*
SOCS1

P

P

#

ATM

PM

JAK2 *

* JAK1

HL, DLBCL, FL, MCL, and BL

C)

HL,FL, and DLBCL

KMT2D

CREBBP

#

F)

DLBCL (N1 and BN2 subtypes), MCL

Loss of histone
acetylation

#

NOTCH1

*

NOTCH2

*

Aberrant activation of
NOTCH signaling

BL

G)
ID3

#

PI3K

Aberrant activation of
PI3K signaling

TCF3

*
CCND3

Aberrant cell cycle
activation

Figure 1. Mutated genes and affected pathways or biological processes in Hodgkin’s lymphoma and B cell non-Hodgkin’s lymphoma
subtypes. HL: Hodgkin’s lymphoma; DLBCL: diffuse large B cell lymphoma; ABC: activated B cell type; GCB: germinal center B cell
type; FL: follicular lymphoma; MCL: mantle cell lymphoma; BL: Burkitt lymphoma; *: gain of function mutations; #: loss-of-function
mutations; P: phosphate; R: restriction point; PM: plasma membrane.

genetically and biologically distinct. Uncontrolled,
constitutive activation of the prosurvival NF-κB signaling
pathway was observed in the ABC DLBCL subtype but not
in GCB DLBCL cases (Davis et al., 2001). Indeed, CARD11
mutations associated with activation of NF-kB were
identified in approximately 10% of ABC DLBCL cases
(Lenz et al., 2008) (Figure 1A). In ABC DLBCL cases, the
NF-κB signaling pathway can continuously be activated
by ‘chronic’ stimulation of the B cell receptor (BCR), and
somatic mutations of two BCR subunits (i.e. CD79A and
CD79B) may contribute to this oncogenic activation (Davis
et al., 2010) (Figure 1D). In more than half of ABC DLBCL
cases, deletions or inactivating mutations in the TNFAIP3
(A20) tumor suppressor gene and genetic defects in some
other protooncogenes and tumor suppressor genes that
regulate the NF-κB signaling pathway were found to have
activated this signaling pathway irregularly (Compagno et
al., 2009). Moreover, oncogenic MYD88 mutations leading
to constitutive activation of the JAK-STAT signaling
pathway were observed very frequently in ABC DLBCL
cases (Ngo et al., 2011). A very recent study by Jain et
al. identified a novel protooncogene called TCF4 (E2.2),
which is located in the recurrently gained 18q21.2 locus
in ABC DLBCL cases. Overexpression of TCF4 by Jain et
al. showed direct transcriptional activation of MYC and
IGHM genes in ABC DLBCL cell lines and cytotoxicity
when it was knocked down (Jain et al., 2019).

t(14;18)(q32;q21) translocation that increases BCL2
expression was detected in 20% of DLBCL cases (Willis
and Dyer, 2000). Importantly, point mutations and indels
of BCL2 were reported in GCB type DLBCL cases (Schuetz
et al., 2012). The BCL6 protooncogene was observed to
be deregulated due to t(3;14)(q27;q32) translocation
in 5%–10% of DLBCL cases (Willis and Dyer, 2000).
Additionally, somatic mutations in BCL6 disrupting the
negative autoregulation of its expression were reported
in DLBCL cases (Pasqualucci et al., 2003). It is important
to note that some of the most critical genetic alterations
specifically detected in GCB DLBCL cases to date were
the point mutations affecting the oncogenic histone
methyltransferase EZH2 on the Tyr641 residue in 21.7% of
GCB DLBCL cases (Morin et al., 2010) (Figure 1E). EZH2
Tyr641 gain-of-function mutations were shown to increase
H3K27 trimethylation, and this chromatin modification
may be responsible for the silencing of tumor suppressor
genes in mutated DLBCL cases (Yap et al., 2011). The
major genetic aberrations observed in DLBCL cases are
shown in Table 2.
As a result of the above-mentioned studies that reveal
differences in genomic, transcriptomic, biological, and
clinical characteristics in ABC and GCB type DLBCL
cases, the WHO provisionally defined the ABC and
GCB types as 2 distinct subclasses of DLBCL. However,
some other DLBCL subtypes were also recognized by

3

ESMERAY and KÜÇÜK / Turk J Biol
Table 1. The major genetic aberrations identified in Hodgkin’s lymphoma.
Lymphoma
type

Hodgkin’s
lymphoma

Classical
Hodgkin’s
lymphoma

EBV+ Hodgkin’s
lymphoma

Gene

Genetic aberration

Dysregulated
Frequency of
biological process or
mutated cases (%)
pathway

References

REL

Amplification

~50

Barth et al., 2003
NF-κB pathway

NFKBIA, NFKBIE, Point mutations,
TNFAIP3
deletions

50–60

MDM2

Gains

60

TP53

Point mutations,
deletions

10

JAK1, STAT3,
STAT5B

Missense mutations

15

JAK2

Gains

32

PTPN1

Splice-acceptor,
missense mutations

6

SOCS1

Frameshift mutations,
disruptive in-frame
deletions, splice donor,
missense

47

JAK-STAT5
pathway

Weniger et al., 2006;
Tiacci et al., 2018

LMP2A

EBV-encoded LMP2A
mediated transcriptional
changes

~50

Transcriptional
signature similar to
that of HRS* cells

Portis et al., 2003

P53-dependent
biological processes
(e.g., cell cycle arrest
and apoptosis)

Weniger et al., 2016

Küppers, 2009

Tiacci et al., 2018
JAK-STAT pathway

*: Reed–Sternberg cells of Hodgkin’s lymphoma.

WHO based on other characteristics such as presence
of chronic inflammation or viral infection in primary
tumors (Swerdlow et al., 2016). Although the molecular
classification dividing DLBCL into the ABC and GCB
subgroups is generally accepted, 10%–20% of cases
cannot be classified using this method (Dubois and
Jardin, 2018). While discussions on DLBCL subtypes
persist, a quaternary molecular classification system for
DLBCL has recently been proposed based on results of
extensive genomic and transcriptomic analyses. Subtype
nomenclature proposed for this classification is as follows:
MCD for MYD88, L265P, and CD79B mutated cases; BN2
for BCL6 fusion genes or NOTCH2 mutated cases; N1 for
NOTCH1 mutated cases; and EZB for EZH2 mutated or
BCL2 translocated cases (Schmitz et al., 2018) (Figure
1F). This newly proposed classification method stemming
from various oncogenic mutations frequently observed in
DLBCL cases aims to ensure selection of more appropriate
treatment approaches for genetically and clinically
heterogeneous DLBCL cases, thereby improving ABC and
GCB classification instead of replacing these two subtypes.
3.2. Follicular lymphoma
Follicular lymphoma (FL) is the most common type of
indolent lymphoma, and it is the second most frequent
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lymphoma among all NHLs after DLBCL (Shankland et
al., 2012). Like other B cell NHL subtypes, development
of FL is thought to be associated with irregularities in
somatic hypermutation and class switch recombination
mechanisms functional during GCB reaction. The most
characteristic genetic alteration of FL is the t(14; 18)
(q32; q21) IGH/BCL2 translocation that brings the active
enhancer of the immunoglobulin heavy chain gene (IGH)
closer to the BCL2 gene (Tsujimoto et al., 1984). This
translocation contributes to FL development through
inhibition of apoptosis due to irregular, high expression
of the antiapoptotic BCL2 gene product (Capaccioli et al.,
1996). t(14; 18) (q32; q21) translocation is observed in 70%
to 95% of FL cases, and is used as a diagnostic biomarker
of FL that can be detected by routine cytogenetic analyses
(Einerson et al., 2005). Recent genomic analyses of FL cases
have revealed mutations related to lymphomagenesis in
genes of the JAK-STAT and NF-κB signaling pathways as
well as in genes involved in posttranslational modification
of histones such as CREBBP, EZH2, and KMT2D (MLL2)
(Okosun et al., 2014) (Figure 1E). More than 50% of FL
cases may show histological transformation to more
aggressive cancers such as DLBCL and Burkitt lymphoma
(Kridel et al., 2012). The life expectancy in cases of
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Table 2. The major genetic aberrations observed in diffuse large B cell lymphoma.
Lymphoma type

Gene

Genetic aberration

Frequency of
mutated cases (%)

Dysregulated biological
process or pathway

DLBCL

BCL2

t(14;18)(q32;q21)

20

Intrinsic pathway of
apoptosis

Willis et al., 2000

GCB DLBCL

BCL2

Point mutations, indels

43

Intrinsic pathway of
apoptosis

Schuetz et al., 2012

DLBCL

BCL6

t(3;14)(q27;q32)

5–10

Germinal center B cell
reaction

Willis et al., 2000

DLBCL

BCL6

Somatic point mutations

16

Disruption of negative
autoregulation of BCL6
expression

CARD11

Missense mutations in
coiled-coil domain

9.6

NF-κB pathway

CD79B

Y196 ITAM mutation,
ITAM deletion

21

CD79A

ITAM deletion, splice site
2.9
mutation

GCB DLBCL

EZH2

DLBCL

ABC DLBCL

References

Pascualucci et al., 2003
Lenz et al., 2008

Chronic BCR signaling,
NF-κB pathway

Davis et al., 2010;
Schmitz et al., 2018

Point mutations on Tyr641 21.7

Trimethylation of Lys27
of histone H3 (H3K27)

Morin et al., 2010

MYC

t(8;14)(q24;q32)

10

G1 phase of the cell cycle

Willis et al., 2000

ABC DLBCL

MYD88

Missense mutations

37

JAK-STAT pathway

Ngo et al., 2011;
Schmitz et al., 2018

DLBCL (N1 and
BN2 subtypes)

NOTCH1,
NOTCH2

Frameshift truncating
mutations

11.7

Notch signaling pathway

Arcaini et al., 2015

ABC DLBCL

TNFAIP3
(A20)

Nonsense mutations,
frameshift indels, splice
site mutations, deletions

~55

NF-κB pathway

Compagno et al., 2009

ABC DLBCL

TCF4

Gain/amplification

40.7

Transcriptional activator
of IGHM and MYC

Jain et al., 2019

ABC: Activated B cell type; GCB: germinal center B cell type; ITAM: immunoreceptor tyrosine-based activation motif; BCR: B cell
receptor.

transformed FL (tFL) is as short as 1.7 years (Al-Tourah
et al., 2008); therefore, ongoing investigations focus
on identification of genetic alterations associated with
histological transformation. Somatic point mutations of
BCL2 (Matolcsy et al., 1996; Correia et al., 2015), TP53
(Lo Coco et al., 1993), miR-142, and MEF2B (Bouska
et al., 2017) genes were reported to be associated with
this transformation. Table 3 lists the recurrent genetic
alterations observed in FL and/or tFL cases.
A recent article published by Andor et al. analyzed
the transcriptome of 34,188 cells from 6 primary FL
tumors to better understand the complexity of FL tumor
biology for identification of novel, more effective targeted
therapeutic approaches (Andor et al., 2019). In malignant

B cell clones, the authors observed overexpression of
BCL2 and downregulation of CD52, FCER2, and MHC
class II genes compared with the expression in normal
B cells from the same patients. In the same single-cell
RNA-Seq study, the authors also focused on expression
profiles in tumor-infiltrating T cells, which showed genes
simultaneously expressed with immune checkpoint
molecules in regulatory T cells. This single cell-based
study showed different subclones, implying intratumoral
genetic heterogeneity of primary FL tumor tissues.
3.3. Burkitt lymphoma
Burkitt lymphoma (BL) is an aggressive type of pediatric
and adult B cell lymphoma originating from GCB cells
(Deffenbacher et al., 2012). Pediatric BL is the most
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Table 3. Recurrent genetic alterations identified in follicular lymphoma, Burkitt lymphoma, and mantle cell lymphoma.
Lymphoma
type

Gene

Genetic aberration

Frequency of mutated
cases (%)

Dysregulated biological
process or pathway

BCL2

t(14;18)(q32;q21)

~80

Tsujimoto et al.,
Intrinsic pathway of apoptosis 1984; Willis et al.,
2000

CREBBP

64

Histone acetylation patterns

EZH2

20

H3K27me3 repressive marks

81

Histone lysine methylation
patterns

KMT2D
(MLL2)
SOCS1
Follicular and/
or transformed
follicular
lymphoma

Somatic
nonsynonymous
mutations

8

6

JAK-STAT signaling

12

MEF2B

20

B cell transcription factor

PAPOLG

24 in FL, 30 in tFL

Polyadenylation of transcripts Kurşun et al., 2019

24 in FL, 30 in tFL

DNA damage induced
NFκB pathway

MYC

15.7 in FL, 29.1 in tFL

Cell cycle and other
oncogenic pathways

TP53

12 in FL, 22 in tFL

P53 dependent cell cycle
arrest and apoptosis

Gain/amplification

Deletion

TNFAIP3

Mantle cell
lymphoma

Okosun et al.,
2014

STAT6

REL

Burkitt
lymphoma

References

Bouska et al., 2017

Hu et al., 2017

Bouska et al.,
2014

NF-κB pathway

CCND3

Missense, nonsense,
indel mutations

ID3

Missense, nonsense, cyrptic
58.5
splice site mutations

Pro-survival PI3 pathway, cell Schmitz et al.,
cycle
2012

TCF3
(E2A)

Missense mutations

29.2

Pro-survival PI3 pathway, cell
cycle

MYC

t(8;14)(q24;q32)

100

c-MYC target genes involved
in cell cycle regulation,
Willis et al., 2000
metabolism etc.

ATM

Deletion, deleterious
point mutations

75

DNA damage response

Schaffner et al.,
2000

CCND1

t(11;14)(q13; q32)

95

P53

Missense mutations

15

G1-S cell cycle transition
P53 dependent cell cycle
arrest and apoptosis

Willis et al., 2000
Greiner et al.,
1996

NOTCH1

Truncating mutations,
frameshifting indels

12

NOTCH signaling pathway

Kridel et al., 2011

BIRC3

Deletion, splice site
mutations

10

Apoptosis

MEF2B

Missense mutations
(p.K23R and p.N49S)

7

Unknown

NOTCH2

Truncating mutations

5

NOTCH signaling pathway

WHSC1

Missense mutations
14
(p.E1099K and p.T1150A)

14.6

G1-S cell cycle transition

Altered methylation of
H3K36

Beà et al., 2013
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common type of childhood B cell NHL, accounting
for 80% of all childhood B cell NHLs (Minard-Colin et
al., 2015). BL is clinically classified into three subtypes:
sporadic, endemic, and immunodeficiency-related
(Piccaluga et al., 2011). The most characteristic genetic
aberration associated with BL cases is the juxtaposition
of the IgH enhancer and MYC protooncogene due to t(8;
14) translocation, which leads to high and constitutive
expression of MYC (Joos et al., 1992). MYC-induced
apoptosis in BL cells is not functional in one-third of BL
cases due to deletions or point mutations of P53 (Gaidano
et al., 1991). For P53 WT BL cases, MDM4, which is located
in the recurrently gained 1q locus, has recently been found
to be overexpressed and to inhibit MYC-induced apoptosis
through inhibition of P53 (Hüllein et al., 2019).
Oncogenic CCND3 mutations stabilizing CCND3
protein isoforms and thereby disrupting cell cycle
progression were identified in 38% of sporadic BL (sBL)
cases (Schmitz et al., 2012). In the same study, mutations
in the TCF3 (E2A) transcription factor or its negative
regulator, ID3, were reported in 70% of sBL cases (Figure
1G). It was proposed that mutated TCF3 contributes to
BL formation by stimulating survival through irregular
activation of the phosphatidyl inositol-3-OH kinase
(PI3K) signaling pathway (Schmitz et al., 2012). Another
whole-genome and whole-exome sequencing-based study
reported mutations in SWI/SNF family genes involved in
chromatin remodeling such as ARID1A and SMARCA4,
as well as those in CCT6B, SALL3, FTCD, and PC genes
(Love et al., 2012). The major genetic aberrations and the
biological processes affected by these alterations in BL
cases are shown in Table 3.
One of the most critical characteristic features of BL
is the presence of EBV in the genome of most BL tumors,
especially in the endemic subtype (Shannon-Lowe et
al., 2017). Integrative analyses of whole-genome and
transcriptomic profiles have recently shown that EBVpositive tumors show a robust increase in abnormal
somatic hypermutation in pediatric endemic and sporadic
BL cases (Grande et al., 2019). This study has also shown
genetic alterations in genes affecting BCR/PI3K signaling,
MYC regulation, apoptosis, the SWI/SNF complex, and
G-protein coupled receptor (GPCR) signaling. Another
study also showed inactivating mutations in components
of the GPCR signaling pathway (i.e. GNA13 and RHOA)
genes, suggesting that this pathway may be a target of
therapy for GNA13 or RHOA-mutated BL cases (O’Hayre
et al., 2016).
3.4. Mantle cell lymphoma
Mantle cell lymphoma (MCL) is a type of lymphoid cancer
originating from neoplastic transformation of naive B cells
that do not encounter antigens (Cortelazzo et al., 2012).
MCLs are highly heterogeneous with respect to their

morphological, clinical, and pathological characteristics.
One of the most characteristic genetic alterations of MCL is
the t(11; 14)(q13; q32) chromosomal translocation, which
increases CCND1 expression that stimulates the cell cycle
(Cortelazzo et al., 2012) (Figure 1C). Interestingly, highly
proliferative MCL tumors express shorter but more stable
versions of CCND1, generated through genomic deletions
or point mutations ending up with shorter 3’ untranslated
regions, which in turn results in poor survival of MCL
patients (Wiestner et al., 2007). A recent study by Mohanty
et al. investigated the consequence of CCND1 coding
sequence point mutations (i.e. E36K, Y44D, or C47S) and
they observed improved stability of CCND1 protein in
these mutated MCL cells (Mohanty et al., 2016).
MCL can be clinically indolent or aggressive; the 5-year
overall survival rate is approximately 60% in the low-risk
group, whereas it decreases significantly in moderate or
high-risk groups (Hoster et al., 2008). MCL was proposed
to develop in 2 distinct ways. Classical MCL usually
consists of SOX11+ cases with no IGHV gene mutations.
On the other hand, other MCLs derive from cells with
IGHV mutation but not SOX11 expression (Swerdlow et
al., 2016).
Previous studies have shown that deletions and
inactivating mutations in the tumor suppressor ATM
(Schaffner et al., 2000) or TP53 (Greiner et al., 1996) may
play a role in MCL development (Figure 1C). The impact
of inactivating mutations of P53 may not be limited with
MCL lymphomagenesis. Eskelund et al. reported that P53
mutation status is an important factor for increasingly
poor prognosis of younger MCL patients, for which P53
mutations confer resistance to rituximab or autologous
stem cell transplantation (Eskelund et al., 2017). Wholetranscriptome analyses of MCL tumor samples and cell
lines showed NOTCH1 mutations in 12% of MCL cases
(Kridel et al., 2012). In another NGS-based study, cancerassociated mutations were observed in antiapoptotic
BIRC3, Toll-like receptor 2 (TLR2), chromatin
modification genes (WHSC1, MLL2, and MEF2B), and the
NOTCH2 gene (Beà et al., 2013). Table 3 shows the genetic
alterations associated with the pathogenesis of MCL.
4. Diagnostic, prognostic, and therapeutic implications
of genetic alterations
Several studies revealed a clinical relevance for the
identified genetic alterations in different subtypes of B
cell NHL. These clinically relevant genetic alterations
may be potentially useful in routine diagnosis as well as
in risk stratification during diagnosis. The oncogenic
chromosomal translocations originating from aberrantly
operating class-switch recombination mechanisms are
useful for genetic diagnosis of B cell NHL subtypes
(Lenz et al., 2007). The presence of these chromosomal
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translocations that are specific for certain subtypes of B
cell NHL can be used to evaluate clonality and to facilitate
the diagnosis of the specific subtype of lymphoma.
Interphase FISH is routinely used for detection of t(14;18)
translocation (i.e. IGH-BCL2) in FL (Vaandrager et al.,
2000), t(11;14) translocation (i.e. IGH-CCND1) in MCL
(Monteil et al., 1996), or t(8;14) translocation (i.e. IgHMYC) in BL (Siebert et al., 1998) for diagnostic purposes.
Some of the identified genetic alterations may be
useful to predict patient survival. It has been known for
some time that P53 mutations are associated with poor
patient survival in aggressive B cell lymphomas (Ichikawa
et al., 1997). Several studies have established a relationship
between P53 mutations and poor prognosis for different
B cell lymphoma subtypes. As an example, Zainuddin et
al. reported an inferior survival for GCB DLBCL cases
with P53 mutations (Zainuddin et al., 2009). Another
report showed that P53-mutated MCL cases have a worse
survival rate than that of unmutated ones (Halldórsdóttir
et al., 2011). In support of these previous reports, a
recent study based on metaanalyses showed a general
prognostic significance for P53 mutations in B cell NHLs
(Xu et al., 2017). MYC overexpression due to genetic
aberrancies (e.g., translocation and amplification) can be
used as a prognostic biomarker for certain B cell NHL
subtypes. Based on a recent report, MYC amplifications
or rearrangements can independently predict overall
survival in patients of DLBCL (Quesada et al., 2017).
Application of next-generation sequencing (NGS)-based
technologies such as whole exome sequencing revealed the
genomic mutational landscape of different types of B cell
lymphomas. Detection of these mutations may provide
useful information regarding prognosis or prediction of
response to immunochemotherapy. In one of these NGSbased studies, FFPE tumor samples of DLBCL patients
were screened for the presence of recurrently identified
mutations using high throughput sequencing (Juskevicius
et al., 2017). After that, a relationship was established
between the identified mutations and overall progressionfree and event-free survival in R-CHOP-treated DLBCL
patients, which showed poorer prognosis for patients with
CREBBP and EP300 mutations and a better prognosis for
patients with SOCS1 mutations.
Somatic mutation status may add value to the
traditionally used prognostic indexes in terms of better risk
stratification of B cell NHLs. To address this possibility,
Pastore et al. retrospectively analyzed the mutational
status of tumor samples of 151 follicular lymphoma cases,
which were obtained before patients received the first-line
immunochemotherapy (Pastore et al., 2015). This report
showed that evaluation of the mutation status of seven
cancer-associated genes (i.e. EZH2, ARID1A, MEF2B, EP300,
FOXO1, CREBBP, and CARD11) with deep sequencing
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improved prognostication of follicular lymphoma patients
receiving first-line immunochemotherapy when integrated
into FILIP1 and ECOG prognostic indexes, which in turn
outperformed prognostications performed with FILIPI
alone or FILIPI combined with ECOG performance status.
Genetic alterations and transcriptional signatures
may be used together or separately as biomarkers for
improved diagnosis or prognosis of B cell lymphoma
patients. Whether mutations or transcriptional signatures
should be chosen as biomarkers depends on the potential
of these genetic or transcriptional changes to separate B
cell lymphoma subtypes into more distinct and refined
diagnostic and/or prognostic subgroups. Subclassification
of DLBCL cases into ABC and GCB subgroups using gene
expression profiling may be one of the best examples not
only in terms of improved cancer diagnosis and prognosis
but also for identification of genetic alterations specific for
each subtype. Lenz et al. showed that there are 30 genetic
alterations observed in a DLBCL subtype specific manner
(Lenz et al., 2008). For instance, INK4a/ARF tumor
suppressor loci deletions were identified mainly in the
ABC DLBCL subtype. On the other hand, PTEN deletions
were observed in the GCB but not in the ABC subtype of
DLBCL (Lenz et al., 2008). Overall, these observations
suggest that using transcriptomic signatures for DLBCL
subclassification during diagnosis may be superior
to other classifications including genetic alterations.
However, MYC/BCL2 coexpression, which is observed
more commonly in the ABC subtype, was proposed as an
independent prognostic factor regardless of the ABC versus
GCB subtype classification (Hu et al., 2013). DLBCL cases
with MYC/BCL2 coexpression showed remarkably poorer
survival rates when compared to the rest of the cases. It
should be noted that a distinct oncogenic gene expression
signature was identified for the MYC/BCL2 coexpression
group in this study. A transcriptional signature may be
more useful than mutations for subdividing MCL cases
into prognostically distinct diagnostic subgroups. A
thirteen-gene signature including SOX11 was identified to
clearly distinguish indolent and conventional subtypes of
MCL (i.e. iMCL and cMCL, respectively). SOX11 protein
expression status in MCL cases may be useful to distinguish
indolent and conventional subtypes of MCL, which differ
in clinicopathological characteristics, including patient
survival (Fernàndez et al., 2010).
Identification of the aberrant signaling pathways in
the subtypes of B cell lymphoma provides opportunities
for development of targeted therapeutics with fewer side
effects in comparison to traditional chemotherapeutic
approaches. Recent clinical studies have focused on
inhibition of oncogenic pathways for better treatment of B
cell lymphoma patients. JAK-STAT pathway activation is
frequently observed in cHL cases. Consequently, JAK1/2
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inhibitors are already in clinical trials for treatment of
advanced relapsed/refractory HL (Den Neste et al., 2018).
A selective BCL2 inhibitor (venetoclax) was evaluated in
106 patients with relapsed or refractory B cell NHL (i.e.
FL, DLBCL, and MCL) as a single agent for its activity and
safety profile; however, future studies are needed maximize
the therapeutic benefits for these patients (Davids et al.,
2017). Genetic alterations in epigenetic regulatory genes
offer significant therapeutic opportunities for treatment
of FL and DLBCL patients with relapsed or refractory
disease. To address this possibility, Italiano et al. recently
investigated an EZH2 inhibitor (i.e. tazemetostat) in
relapsed and refractory B cell NHL patients (Italiano et
al., 2018). Based on these results, it was concluded that
tazemetostat has a favorable safety profile and antitumor
activity in patients with refractory B cell NHL. One of the
most intriguing results regarding targeted therapeutics
against a constitutively activated oncogenic pathway is
selective inhibition of the chronic BCR signaling with
ibrutinib in DLBCL. Consistent with the chronic activation
of BCR signaling selectively in the ABC DLBCL subtype,
ABC DLBCL patients responded significantly better to
this BCR signaling inhibitor in comparison to patients
with the GCB DLBCL subtype (Wilson et al., 2015). These
and other similar studies show that genetic alterations
that activate oncogenic signaling pathways may be
pharmacologically targeted to improve currently available
therapeutic options such that B cell lymphoma patients in
advanced stages may benefit from more effective and safer
treatment alternatives.
5. Chemotherapy resistance-associated genetic
aberrations in B cell NHL
One of the most important challenges in the treatment of
B cell lymphoma patients is the resistance that develops
against
chemotherapy
or
immunochemotherapy
treatment. After inclusion of rituximab in the traditional
CHOP (cyclophosphamide, doxorubicin, vincristine, and
prednisone) chemotherapy, CHOP therapy resistance
was eliminated in many B cell lymphoma cases. Mounier
et al. reported that R-CHOP therapy overcomes therapy
resistance associated with BCL2 overexpression in elderly
DLBCL patients (Mounier et al., 2003). A report by Liu et
al. showed that PRDM1β is expressed in a subset of nonGCB-like DLBCL cases, and its expression is associated
with poor survival in CHOP-treated but not R-CHOPtreated DLBCL cases. They further showed that rituximab
downregulates PRDM1β expression in vitro (Liu et al.,
2007). However, DLBCL cases may develop resistance to
R-CHOP therapy. Yuan et al. showed that high microRNA125b and microRNA-130a levels in the serum of DLBCL
cases are associated with R-CHOP resistance in DLBCL
cases (Yuan et al., 2016). Laursen et al. showed that high

expression of CXCR4 on the tumor cell surface may be
responsible for R-CHOP resistance in a subset of DLBCL
cases (Laursen et al., 2019). Another study by Wilson
et al. asked whether ABC DLBCL patients who have
chemotherapy refractory disease can be treated through
inhibition of BCR signaling. They performed a clinical
trial with ibrutinib and observed a high response in those
patients, especially in the presence of MYD88 mutations
(Wilson et al., 2015).
Follicular lymphoma cases may transform into
high-grade lymphomas called transformed follicular
lymphomas (tFL) such as DLBCL or BL, which are often
chemotherapy-resistant (Lossos and Gascoyne, 2011).
Many genetic alterations in FL tumors such as deletions
of P53, P16/CDK2NA, or deregulations of MYC have been
associated with FL to tFL transformation (Lossos and
Gascoyne, 2011). Given the increased chemoresistance
after histological transformation, these genetic alterations
may also be responsible for chemotherapy resistance.
Based on genome-wide copy number analyses of 198 FL
and 79 tFL cases using SNP arrays, Bouska et al. identified
recurrent chromosomal gains or losses in FL cases that
can be potentially associated with tFL transformation.
These chromosomal gains and losses may restrict immune
surveillance and deregulate P53 or NFκB pathways
(Bouska et al., 2014). REL is one of the protooncogenes
identified to reside on the frequently amplified 2p16.1-p15
locus in FL and tFL cases based on this study. Recently,
Hu et al. showed that FL cases with high REL expression
levels may be associated with chemotherapy resistance
due to activation of DNA damage-induced repair and cell
cycle arrest pathways; however, future studies are needed
to investigate whether REL is a predictive biomarker of
chemotherapy in FL and/or tFL cases (Hu et al., 2017).
Another recent study systematically analyzed genes in the
frequently amplified 2p16.1-p15 locus by integrating an
SNP array and gene expression profiling data of previously
published reports on FL and tFL cases to address
whether there are genes other than REL that may act as
protooncogenes during transformation to tFL (Kurşun
and Küçük, 2019). This study showed that PAPOLG is a
candidate protooncogene for FL development, and it may
have a role during histological transformation to tFL.
Current efforts in MCL genomics focus on
identification of mutations associated with chemotherapy
or immunochemotherapy resistance. To identify genetic
alterations associated with therapy resistance in MCL
cases, Wu et al. performed genome-wide analyses of
MCL tumors which revealed cancer-related mutations
at the time of diagnosis, as well as relapse (Wu et al.,
2016). They identified recurrent CARD11 mutations in
5.5% of MCL cases. More importantly, overexpression of
mutated CARD11 constructs in MCL cell lines conferred
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resistance to ibrutinib and lenalidomide, which are
inhibitors of BCR and NF-κB signaling, respectively.
Similarly, CCND1 mutations described in MCL cases
by Mohanty et al. conferred therapeutic resistance to
ibrutinib, a bruton tyrosine kinase inhibitor used for MCL
treatment (Mohanty et al., 2016). Agarwal et al. focused
on the genomic profiles of MCL patients who respond or
did not respond to ibrutinib and venetoclax combinatory
therapy and identified a distinct genomic profile separating
responders from nonresponders. Based on this very
recent study, chemotherapy-resistant patients harbor
9p21.1–p24.3 locus deletion and/or mutations of the genes
forming the SWI–SNF chromatin-remodeling complex
(Agarwal et al., 2019). They observed that defective SWI–
SNF complexes promote transcriptional upregulation of
BCL-XL, which may confer resistance to the ibrutinib and
venetoclax combination. This study is a good example of
precision medicine and shows that individual patients’
tumor genotypes can be used to decide on the most
appropriate therapy.
6. Noninvasive clinical applications of genomic
alterations of B cell lymphoma for diagnosis, prognosis,
or disease monitoring
Traditional diagnosis of B cell lymphoma subtypes requires
immunohistochemical and histopathological analyses
of tumor biopsy sections. Tumor biopsies are obtained
from lymphoma patients using invasive methodologies,
which may have the following specific disadvantages:
1) procedures are generally time-consuming; 2) tissue
sampling is localized; therefore, the obtained tissue may not
reflect the genetic characteristics and heterogeneity of the
entire tumor tissue present in the patient; 3) tumor biopsies
may not always be easy to obtain; 4) patients may have
some pain. Due to these disadvantages, cancer researchers
have been trying to address whether body liquids (e.g.,
blood and saliva) contain tumor-derived biomolecules that
reflect the genetic characteristics of solid tumor tissues of
cancer patients. Circulating cell-free DNA (cfDNA) has
proven not only to be useful in terms of overcoming the
disadvantages of standard biopsy listed above but has also
provided the opportunity to track genetic changes through
multiple, periodical blood sampling and determine the
emergence of therapy-resistant clones several months
earlier than currently used methods in routine clinical
settings (Crowley et al., 2013).
Several recently reported elegant studies have revealed
the feasibility of cfDNA genotyping for diagnosis,
prognosis, and monitoring chemotherapy response in
major subtypes of B cell lymphoma. Spina et al. evaluated
whether circulating cell-free tumor DNA can be used for
cHL genotyping (Spina et al., 2018). By applying a customdesigned, ultradeep targeted NGS panel, which consisted
of 77 genes recurrently mutated in B cell tumors, on
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DNA samples from 80 diagnosed and 32 refractory cHL
cases, the authors observed that 87.5% of the somatic
mutations detected in tumor biopsies were also present
in the circulating cell-free tumor DNA (ctDNA) of the
same patients’ plasma. The same study also revealed that
decreased plasma ctDNA concentrations are associated
with markedly better survival for cHL patients treated with
a combination of chemotherapeutic drugs (i.e. adriamycin,
bleomycin, vinblastine, and dacarbazine). Another recent
study, by Rossi et al., showed that the sensitivity for
detection of mutations in cfDNA is 83% if tumor tissue
gDNA is regarded as the gold standard for mutation
detection, suggesting that noninvasive blood sampling and
subsequent plasma cfDNA genotyping may have diagnostic
value (Rossi et al., 2017). The authors also observed the
changes in variant allele frequency (VAF) before and after
R-CHOP therapy, which showed that patients responding
to R-CHOP have decreased VAF, whereas others did
not. Importantly, new variants emerged in different
patients such as those of PIM1, BIRC3, and FBXW7. This
observation suggests that mutations responsible for relapse
or refractory disease in individual DLBCL patients can
potentially be determined noninvasively using a bloodbased test. From a precision medicine perspective, cfDNA
genotyping may assist clinicians in choosing the most
suitable option for targeted therapy through facilitated
detection of individual genetic subclones responsible for
relapse in DLBCL patients. There are other recent studies
that evaluated plasma cfDNA levels in DLBCL (Kurtz et al.,
2018), addressing whether it can predict or monitor therapy
response or if it can predict tumor burden or prognosis of
FL cases (Delfau-Larue et al., 2018). Using droplet digital
PCR, Alcaide et al. detected previously known mutations
(e.g., EZH2 Y641 and STAT6 D419) in circulating tumor
DNA in major B cell NHL subtypes (Alcaide et al., 2016).
7. Conclusion
HL and B cell NHL, which represent most lymphoid
cancers, include mutations related to malfunctioning
immunogenetic mechanisms during germinal center
reactions. These genetic aberrations may provide us with
novel biomarkers of noninvasive diagnosis or prognosis
if they distinguish B cell lymphoma subsets from similar
B cell lymphomas or benign diseases and predict patient
survival, respectively. Furthermore, biological signaling
pathways dysregulated by activating mutations in B cell
lymphomas offer new opportunities for targeted therapies.
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